-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Downgrades MapLight Therapeutics to Neutral, Lowers Price Target to $13

Benzinga·08/10/2026 19:51:00
语音播报
UBS analyst Ashwani Verma downgrades MapLight Therapeutics (NASDAQ:MPLT) from Buy to Neutral and lowers the price target from $52 to $13.